Encorafenib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 48 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Encorafenib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in the proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in the proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.

Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits the BRAF gene, which encodes for the B-RAF protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [Binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Mechanism of Action

Encorafenib is a kinase inhibitor that specifically targets BRAF V600E, as well as wild-type BRAF and CRAF while tested with in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, including BRAF V600E, result in activated BRAF kinases that may stimulate tumor cell growth. Encorafenib is able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36, and significantly reduce ligand binding to these kinases at clinically achievable concentrations (≤ 0.9 μM). In efficacy studies, sorafenib inhibited the in vitro cell growth of tumor cell lines that express BRAF V600 E, D, and K mutations. In mice implanted with tumor cells expressing the BRAF V600E mutation, sorafenib-induced tumor regressions were associated with RAF/MEK/ERK pathway suppression. Encorafenib and binimetinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared with either drug alone, co-administration of encorafenib and binimetinib results in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. In addition to the above, the combination of encorafenib and binimetinib acted to delay the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared with the administration of either drug alone.

Encorafenib has shown improved efficacy in the treatment of metastatic melanoma. Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. Once-daily dosing of single-agent encorafenib has a distinct tolerability profile and shows varying antitumor activity across BRAFi-pretreated and BRAFi-naïve patients with advanced/metastatic stage melanoma.

Indications

  • Used in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • Encorafenib indicated in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy
  • Treatment of colorectal carcinoma
  • Treatment of melanoma
  • Metastatic Colorectal Cancer (CRC)
  • Metastatic Melanoma
  • Unresectable Melanoma

Use in Cancer

Encorafenib is approved to be used with other drugs to treat patients whose cancer has a certain mutation in the BRAF gene, including:

  • Colorectal cancer has spread to other parts of the body. It is used with cetuximab in adults who have received previous treatment.
  • Melanoma. It is used with binimetinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.

Encorafenib is also being studied in the treatment of other types of cancer.

Contraindications

  • have untreated low potassium or low magnesium in your blood
  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • fluid in the covering of the heart or pericardium
  • chronic heart failure
  • escape of fluid into the lungs
  • fluid in the lungs
  • liver problems
  • fluid retention in the legs, feet, arms or hands
  • high amount of jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin in the blood
  • excessive diarrhea
  • abnormal liver function tests
  • pregnancy

Dosage

Strengths: 50 mg; 75 mg

Melanoma – Metastatic

  • 450 mg orally once a day in combination with binimetinib until disease progression or unacceptable toxicity
  • If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 mg once a day until binimetinib is resumed.
  • Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating therapy
  • Refer to the binimetinib prescribing information for recommended dosing information.

Colorectal Cancer

  • 300 mg orally once a day in combination with cetuximab until disease progression or unacceptable toxicity
  • Confirm the presence of a BRAF V600E mutation in tumor specimens prior to initiating therapy.
  • Refer to the cetuximab prescribing information for recommended dosing information.

Dose Adjustments

BRAF V600E OR V600K MUTATION-POSITIVE UNRESECTABLE OR METASTATIC MELANOMA:

  • If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 orally mg once a day until binimetinib is resumed.
  • If cetuximab is discontinued, discontinue binimetinib.

RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS for BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma:

  • First dose reduction: 300 mg orally once a day
  • Second dose reduction: 225 mg orally once a day
  • Subsequent modification: Permanently discontinue this drug if unable tolerate 225 mg once a day.

BRAF V600E MUTATION-POSITIVE METASTATIC COLORECTAL CANCER (CRC):

  • If cetuximab is discontinued, discontinue binimetinib.

RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS for BRAF V600E MUTATION-POSITIVE METASTATIC CRC:

  • First dose reduction: 225 mg orally once a day
  • Second dose reduction: 150 mg orally once a day
  • Subsequent modification: Permanently discontinue this drug if unable tolerate 150 mg once a day.

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma and BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC):
NEW PRIMARY MALIGNANCIES:

  • Non-cutaneous RAS mutation-positive malignancies: Discontinue this drug.

UVEITIS:

  • Grade 1 through 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks; if improved, resume at same or reduced dose; if not improved, permanently discontinue this drug.
  • Grade 4: Permanently discontinue therapy.

QTc PROLONGATION:

  • QTcF greater than 500 milliseconds (ms) and less than or equal to 60 ms increase from baseline: Withhold this drug until QTcF is less than or equal to 500 ms; resume at reduced dose; if more than one recurrence, permanently discontinue this drug.
  • QTcF greater than 500 ms and greater than 60 ms increase from baseline: Permanently discontinue this drug.

HEPATOTOXICITY:

  • Grade 2 AST or ALT increased: Maintain the dose; if no improvement within 4 weeks, withhold this drug until improvement to Grade 0 or 1 or to pretreatment/baseline levels and then resume at same dose.
  • Recurrent Grade 2 or first occurrence of any Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks; if improvement to Grade 0 or 1 or to pretreatment/baseline level, resume at reduced dose; if no improvement, permanently discontinue this drug.
  • First occurrence of any Grade 4 AST or ALT increase: Permanently discontinue this drug OR withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
  • Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug.
  • Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug.

DERMATOLOGIC:

  • Grade 2: If no improvement within 2 weeks, withhold this drug until Grade 0 or 1; resume at same dose.
  • Grade 3: Withhold this drug until Grade 0 or 1; resume at same dose if first occurrence or reduce dose if recurrent.
  • Grade 4: Permanently discontinue this drug.

OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE):

  • Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
  • First occurrence of any Grade 4: Permanently discontinue this drug OR withhold for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug.
  • Recurrent Grade 3: Consider permanently discontinuing this drug.
  • Recurrent Grade 4: Permanently discontinue this drug.

DOSE MODIFICATIONS FOR COADMINISTRATION OF STRONG OR MODERATE CYP450 3A4 INHIBITORS:
Avoid concurrent use of strong or moderate CYP450 3A4 inhibitors during therapy with this drug. If concomitant use of a strong or moderate CYP450 3A4 inhibitor is unavoidable, reduce the dose of this drug as follows:
Current daily dose 450 mg:

  • Dose for coadministration with moderate CYP450 3A4 inhibitor: 225 mg
  • Dose for coadministration with strong CYP450 3A4 inhibitor: 150 mg

Current daily dose 300 mg:

  • Dose for coadministration with moderate CYP450 3A4 inhibitor: 150 mg
  • Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg

Current daily dose 225 mg:

  • Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg
  • Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg

Current daily dose 150 mg:

  • Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg
  • Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg

*NOTE: Encorafenib exposure at the 75 mg daily dose when coadministered with a strong CYP450 3A4 inhibitor is expected to be higher than at the 150 mg daily dose in the absence of a CYP450 3A4 inhibitor and similar to exposure at the 225 mg daily dose in the absence of a CYP450 3A4 inhibitor. Monitor patients closely for adverse reactions and use clinical judgement when using encorafenib with strong CYP450 3A4 inhibitors at the 150 mg dose level.

Side Effects

The Most Common

  • fatigue
  • fever
  • nausea
  • vomiting
  • stomach pain
  • constipation
  • decreased appetite
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • dizziness
  • skin thickening
  • rash
  • dry or itchy skin
  • hair loss
  • joint or muscle pain
  • change in taste
  • back, arm, or leg pain
  • acne
  • numbness, burning or tingling in the arms, hands, feet, or legs
  • difficulty falling asleep or staying asleep
  • dizziness, fainting or feeling faint
  • vision changes
  • skin changes such as a new wart, a sore or reddish bump that does not heal, a change in the size or color of a mole
  • unusual bleeding or bruising
  • black, tarry, or bloody stools
  • coughing up blood
  • nose bleeding
  • redness, swelling, numbness, and skin peeling of hands and soles of feet

More Common

  • eye pain or swelling, vision changes, seeing halos around lights, seeing color “dots” in your vision;
  • severe skin rash, skin pain or swelling, redness, and peeling skin on your hands or feet;
  • fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out); or
  • signs of bleeding–weakness, dizziness, pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache, nosebleeds, rectal bleeding, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
  • nausea, vomiting, stomach pain;
  • tiredness; or
  • joint pain or swelling.

Rare

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • eye pain,
  • swelling of the eye,
  • vision changes,
  • seeing halos around lights,
  • seeing color “dots” in your vision,
  • severe skin rash,
  • skin pain or swelling,
  • redness and peeling skin on your hands or feet,
  • fast or pounding heartbeats,
  • fluttering in your chest,
  • shortness of breath,
  • sudden dizziness,
  • weakness,
  • dizziness,
  • headache,
  • nosebleeds,
  • rectal bleeding,
  • bloody or tarry stools,
  • coughing up blood, and
  • vomit that looks like coffee grounds

Drug Interaction

Pregnancy and Lactation

TGA pregnancy category D:

US FDA pregnancy category Not Assigned

Pregnancy

Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

Lactation

The effects in the nursing infant are unknown. Women should be advised not to breastfeed during therapy with this drug and for 2 weeks after the final dose.

How should this medicine be used?

Encorafenib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take encorafenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take encorafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with encorafenib.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking encorafenib,

  • tell your doctor and pharmacist if you are allergic to encorafenib, any other medications, or any of the ingredients in encorafenib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor what herbal products you are taking, especially St John’s wort.
  • tell your doctor if you have or have ever had a QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), low levels of potassium or magnesium in your blood, heart failure, or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant. You will have to take a pregnancy test before starting treatment. You should use a nonhormonal birth control to prevent pregnancy during your treatment with encorafenib and for 2 weeks after your final dose. Encorafenib may decrease the effectiveness of oral contraceptives (birth control pills), so it is especially important to use a nonhormonal form of birth control. Talk to your doctor about methods of birth control that will work for you. If you become pregnant while taking encorafenib, call your doctor immediately. Encorafenib may harm the fetus.
  • tell your doctor if you are breastfeeding. Do not breastfeed while you are taking encorafenib and for 2 weeks after your final dose.
  • you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of taking encorafenib.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Encorafenib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Encorafenib is a kinase inhibitor that specifically targets BRAF V600E, as well as wild-type BRAF and CRAF while tested with in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, including BRAF V600E, result in activated BRAF kinases that may stimulate tumor cell growth. Encorafenib is able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36, and significantly reduce ligand binding to these kinases at clinically achievable concentrations (≤ 0.9 μM). In efficacy studies, sorafenib inhibited the in vitro cell growth of tumor cell lines that express BRAF V600 E, D, and K mutations. In mice implanted with tumor cells expressing the BRAF V600E mutation, sorafenib-induced tumor regressions were associated with RAF/MEK/ERK pathway suppression. Encorafenib and binimetinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared with either drug alone, co-administration of encorafenib and binimetinib results in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. In addition to the above, the combination of encorafenib and binimetinib acted to delay the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared with the administration of either drug alone. Encorafenib has shown improved efficacy in the treatment of metastatic melanoma. Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. Once-daily dosing of single-agent encorafenib has a distinct tolerability profile and shows varying antitumor activity across BRAFi-pretreated and BRAFi-naïve patients with advanced/metastatic stage melanoma. Indications Used in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib indicated in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy Treatment of colorectal carcinoma Treatment of melanoma Metastatic Colorectal Cancer (CRC) Metastatic Melanoma Unresectable Melanoma Use in Cancer Encorafenib is approved to be used with other drugs to treat patients whose cancer has a certain mutation in the BRAF gene, including: Colorectal cancer has spread to other parts of the body. It is used with cetuximab in adults who have received previous treatment. Melanoma. It is used with binimetinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body. Encorafenib is also being studied in the treatment of other types of cancer. Contraindications have untreated low potassium or low magnesium in your blood anemia decreased blood platelets low levels of a type of white blood cell called neutrophils fluid in the covering of the heart or pericardium chronic heart failure escape of fluid into the lungs fluid in the lungs liver problems fluid retention in the legs, feet, arms or hands high amount of bilirubin in the blood excessive diarrhea abnormal liver function tests pregnancy Dosage Strengths: 50 mg; 75 mg Melanoma - Metastatic 450 mg orally once a day in combination with binimetinib until disease progression or unacceptable toxicity If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 mg once a day until binimetinib is resumed. Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating therapy Refer to the binimetinib prescribing information for recommended dosing information. Colorectal Cancer 300 mg orally once a day in combination with cetuximab until disease progression or unacceptable toxicity Confirm the presence of a BRAF V600E mutation in tumor specimens prior to initiating therapy. Refer to the cetuximab prescribing information for recommended dosing information. Dose Adjustments BRAF V600E OR V600K MUTATION-POSITIVE UNRESECTABLE OR METASTATIC MELANOMA: If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 orally mg once a day until binimetinib is resumed. If cetuximab is discontinued, discontinue binimetinib. RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS for BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma: First dose reduction: 300 mg orally once a day Second dose reduction: 225 mg orally once a day Subsequent modification: Permanently discontinue this drug if unable tolerate 225 mg once a day. BRAF V600E MUTATION-POSITIVE METASTATIC COLORECTAL CANCER (CRC): If cetuximab is discontinued, discontinue binimetinib. RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS for BRAF V600E MUTATION-POSITIVE METASTATIC CRC: First dose reduction: 225 mg orally once a day Second dose reduction: 150 mg orally once a day Subsequent modification: Permanently discontinue this drug if unable tolerate 150 mg once a day. BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma and BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC): NEW PRIMARY MALIGNANCIES: Non-cutaneous RAS mutation-positive malignancies: Discontinue this drug. UVEITIS: Grade 1 through 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks; if improved, resume at same or reduced dose; if not improved, permanently discontinue this drug. Grade 4: Permanently discontinue therapy. QTc PROLONGATION: QTcF greater than 500 milliseconds (ms) and less than or equal to 60 ms increase from baseline: Withhold this drug until QTcF is less than or equal to 500 ms; resume at reduced dose; if more than one recurrence, permanently discontinue this drug. QTcF greater than 500 ms and greater than 60 ms increase from baseline: Permanently discontinue this drug. HEPATOTOXICITY: Grade 2 AST or ALT increased: Maintain the dose; if no improvement within 4 weeks, withhold this drug until improvement to Grade 0 or 1 or to pretreatment/baseline levels and then resume at same dose. Recurrent Grade 2 or first occurrence of any Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks; if improvement to Grade 0 or 1 or to pretreatment/baseline level, resume at reduced dose; if no improvement, permanently discontinue this drug. First occurrence of any Grade 4 AST or ALT increase: Permanently discontinue this drug OR withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug. Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug. Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug. DERMATOLOGIC: Grade 2: If no improvement within 2 weeks, withhold this drug until Grade 0 or 1; resume at same dose. Grade 3: Withhold this drug until Grade 0 or 1; resume at same dose if first occurrence or reduce dose if recurrent. Grade 4: Permanently discontinue this drug. OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE): Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug. First occurrence of any Grade 4: Permanently discontinue this drug OR withhold for up to 4 weeks; if improves to Grade 0 or 1 or to pretreatment/baseline level, then resume at reduced dose; if no improvement, permanently discontinue this drug. Recurrent Grade 3: Consider permanently discontinuing this drug. Recurrent Grade 4: Permanently discontinue this drug. DOSE MODIFICATIONS FOR COADMINISTRATION OF STRONG OR MODERATE CYP450 3A4 INHIBITORS: Avoid concurrent use of strong or moderate CYP450 3A4 inhibitors during therapy with this drug. If concomitant use of a strong or moderate CYP450 3A4 inhibitor is unavoidable, reduce the dose of this drug as follows: Current daily dose 450 mg: Dose for coadministration with moderate CYP450 3A4 inhibitor: 225 mg Dose for coadministration with strong CYP450 3A4 inhibitor: 150 mg Current daily dose 300 mg: Dose for coadministration with moderate CYP450 3A4 inhibitor: 150 mg Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg Current daily dose 225 mg: Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg Current daily dose 150 mg: Dose for coadministration with moderate CYP450 3A4 inhibitor: 75 mg Dose for coadministration with strong CYP450 3A4 inhibitor: 75 mg *NOTE: Encorafenib exposure at the 75 mg daily dose when coadministered with a strong CYP450 3A4 inhibitor is expected to be higher than at the 150 mg daily dose in the absence of a CYP450 3A4 inhibitor and similar to exposure at the 225 mg daily dose in the absence of a CYP450 3A4 inhibitor. Monitor patients closely for adverse reactions and use clinical judgement when using encorafenib with strong CYP450 3A4 inhibitors at the 150 mg dose level. Side Effects The Most Common fatigue fever nausea vomiting stomach pain constipation decreased appetite headache dizziness skin thickening rash dry or itchy skin hair loss joint or muscle pain change in taste back, arm, or leg pain acne numbness, burning or tingling in the arms, hands, feet, or legs difficulty falling asleep or staying asleep dizziness, fainting or feeling faint vision changes skin changes such as a new wart, a sore or reddish bump that does not heal, a change in the size or color of a mole unusual bleeding or bruising black, tarry, or bloody stools coughing up blood nose bleeding redness, swelling, numbness, and skin peeling of hands and soles of feet More Common eye pain or swelling, vision changes, seeing halos around lights, seeing color "dots" in your vision; severe skin rash, skin pain or swelling, redness, and peeling skin on your hands or feet; fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out); or signs of bleeding--weakness, dizziness, headache, nosebleeds, rectal bleeding, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds. nausea, vomiting, stomach pain; tiredness; or joint pain or swelling. Rare hives, difficulty breathing, swelling of your face, lips, tongue, or throat, eye pain, swelling of the eye, vision changes, seeing halos around lights, seeing color “dots” in your vision, severe skin rash, skin pain or swelling, redness and peeling skin on your hands or feet, fast or pounding heartbeats, fluttering in your chest, shortness of breath, sudden dizziness, weakness, dizziness, headache, nosebleeds, rectal bleeding, bloody or tarry stools, coughing up blood, and vomit that looks like coffee grounds Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Encorafenib can be increased when it is combined with Abametapir. Abatacept The metabolism of Encorafenib can be increased when combined with Abatacept. Abiraterone The metabolism of Encorafenib can be decreased when combined with Abiraterone. Acebutolol The metabolism of Encorafenib can be decreased when combined with Acebutolol. Acetaminophen The metabolism of Encorafenib can be decreased when combined with Acetaminophen. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Encorafenib. Adalimumab The metabolism of Encorafenib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Encorafenib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Encorafenib. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Encorafenib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Encorafenib. Almotriptan The metabolism of Encorafenib can be decreased when combined with Almotriptan. Alogliptin The metabolism of Encorafenib can be decreased when combined with Alogliptin. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Encorafenib. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Encorafenib. Aminophenazone The metabolism of Encorafenib can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Encorafenib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Amisulpride. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Encorafenib. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Encorafenib. Amoxapine The metabolism of Amoxapine can be decreased when combined with Encorafenib. Amphetamine The metabolism of Encorafenib can be decreased when combined with Amphetamine. Amprenavir The metabolism of Encorafenib can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Anagrelide. Anakinra The metabolism of Encorafenib can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Encorafenib. Antipyrine The metabolism of Encorafenib can be decreased when combined with Antipyrine. Apalutamide The metabolism of Encorafenib can be increased when combined with Apalutamide. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encorafenib. Apremilast The metabolism of Encorafenib can be increased when combined with Apremilast. Aprepitant The metabolism of Encorafenib can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Encorafenib. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Encorafenib. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Encorafenib. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Artemether. Artenimol The metabolism of Encorafenib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Articaine. Asenapine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Asenapine. Astemizole The metabolism of Astemizole can be decreased when combined with Encorafenib. Asunaprevir The metabolism of Encorafenib can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Encorafenib can be decreased when combined with Atazanavir. Atenolol The metabolism of Encorafenib can be decreased when combined with Atenolol. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Encorafenib. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Encorafenib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Encorafenib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Encorafenib. Azelastine The metabolism of Encorafenib can be decreased when combined with Azelastine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Encorafenib. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Encorafenib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Encorafenib. Benzocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Bepridil. Berotralstat The metabolism of Encorafenib can be decreased when combined with Berotralstat. Betaxolol The metabolism of Encorafenib can be decreased when combined with Betaxolol. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Encorafenib. Bimekizumab The metabolism of Encorafenib can be increased when combined with Bimekizumab. Biperiden The metabolism of Encorafenib can be decreased when combined with Biperiden. Boceprevir The metabolism of Encorafenib can be decreased when combined with Boceprevir. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encorafenib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Encorafenib. Brexpiprazole The metabolism of Encorafenib can be decreased when combined with Brexpiprazole. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Encorafenib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Encorafenib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Bupivacaine. Buprenorphine The metabolism of Encorafenib can be decreased when combined with Buprenorphine. Bupropion The metabolism of Encorafenib can be decreased when combined with Bupropion. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Encorafenib. Buspirone The metabolism of Encorafenib can be decreased when combined with Buspirone. Butacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Encorafenib. Canakinumab The metabolism of Encorafenib can be increased when combined with Canakinumab. Cannabidiol The metabolism of Encorafenib can be decreased when combined with Cannabidiol. Capsaicin The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Capsaicin. Carbamazepine The metabolism of Encorafenib can be increased when combined with Carbamazepine. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Encorafenib. Carvedilol The metabolism of Encorafenib can be decreased when combined with Carvedilol. Celecoxib The metabolism of Encorafenib can be decreased when combined with Celecoxib. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Encorafenib. Cenobamate The serum concentration of Encorafenib can be decreased when it is combined with Cenobamate. Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Encorafenib. Cerivastatin The metabolism of Encorafenib can be decreased when combined with Cerivastatin. Certolizumab pegol The metabolism of Encorafenib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Encorafenib. Cevimeline The metabolism of Encorafenib can be decreased when combined with Cevimeline. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Encorafenib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Chloroprocaine. Chloroquine The metabolism of Encorafenib can be decreased when combined with Chloroquine. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Encorafenib. Chlorpromazine The metabolism of Encorafenib can be decreased when combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Encorafenib. Chlorzoxazone The metabolism of Encorafenib can be decreased when combined with Chlorzoxazone. Cholecalciferol The metabolism of Encorafenib can be decreased when combined with Cholecalciferol. Ciclesonide The metabolism of Encorafenib can be decreased when combined with Ciclesonide. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Encorafenib. Cimetidine The metabolism of Encorafenib can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Encorafenib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Encorafenib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Encorafenib. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Encorafenib. Cisapride The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Cisapride. Citalopram The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Citalopram. Clarithromycin The metabolism of Encorafenib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Clemastine. Clevidipine The metabolism of Encorafenib can be decreased when combined with Clevidipine. Clobazam The metabolism of Encorafenib can be decreased when combined with Clobazam. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Encorafenib. Clomipramine The metabolism of Clomipramine can be decreased when combined with Encorafenib. Clonidine The metabolism of Clonidine can be decreased when combined with Encorafenib. Clozapine The metabolism of Encorafenib can be decreased when combined with Clozapine. Cobicistat The metabolism of Encorafenib can be decreased when combined with Cobicistat. Cocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Cocaine. Codeine The metabolism of Encorafenib can be decreased when combined with Codeine. Conivaptan The metabolism of Encorafenib can be decreased when combined with Conivaptan. Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Encorafenib. Curcumin The metabolism of Encorafenib can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Encorafenib. Cyclosporine The metabolism of Encorafenib can be decreased when combined with Cyclosporine. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Encorafenib. Dabrafenib The serum concentration of Encorafenib can be decreased when it is combined with Dabrafenib. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Encorafenib. Danazol The metabolism of Encorafenib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Encorafenib can be decreased when combined with Dapagliflozin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Encorafenib. Darifenacin The metabolism of Encorafenib can be decreased when combined with Darifenacin. Darunavir The metabolism of Encorafenib can be decreased when combined with Darunavir. Dasabuvir The metabolism of Encorafenib can be decreased when combined with Dasabuvir. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Encorafenib. Debrisoquine The metabolism of Encorafenib can be decreased when combined with Debrisoquine. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Encorafenib. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Encorafenib. Delamanid Encorafenib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Encorafenib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Encorafenib. Desipramine The metabolism of Encorafenib can be decreased when combined with Desipramine. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Encorafenib. Desvenlafaxine The metabolism of Encorafenib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Deutetrabenazine. Dexamethasone The metabolism of Encorafenib can be increased when combined with Dexamethasone. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Encorafenib. Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Encorafenib. Dexfenfluramine The metabolism of Encorafenib can be decreased when combined with Dexfenfluramine. Dexmedetomidine The metabolism of Encorafenib can be decreased when combined with Dexmedetomidine. Dextroamphetamine The metabolism of Encorafenib can be decreased when combined with Dextroamphetamine. Dextromethorphan The metabolism of Encorafenib can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Encorafenib can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Encorafenib can be decreased when combined with Diacerein. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Encorafenib. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Encorafenib. Dihydrocodeine The metabolism of Encorafenib can be decreased when combined with Dihydrocodeine. Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Encorafenib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Encorafenib. Dimethyl sulfoxide The metabolism of Encorafenib can be decreased when combined with Dimethyl sulfoxide. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Encorafenib. Dofetilide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Encorafenib. Domperidone The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Domperidone. Donepezil The metabolism of Encorafenib can be decreased when combined with Donepezil. Dosulepin The metabolism of Encorafenib can be decreased when combined with Dosulepin. Doxazosin The metabolism of Encorafenib can be decreased when combined with Doxazosin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Encorafenib. Doxorubicin The metabolism of Encorafenib can be decreased when combined with Doxorubicin. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Encorafenib. Dronabinol The metabolism of Encorafenib can be decreased when combined with Dronabinol. Dronedarone The metabolism of Encorafenib can be decreased when combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Encorafenib. Duloxetine The metabolism of Encorafenib can be decreased when combined with Duloxetine. Dyclonine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Encorafenib. Efavirenz The metabolism of Encorafenib can be decreased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Encorafenib. Eletriptan The metabolism of Encorafenib can be decreased when combined with Eletriptan. Eliglustat The metabolism of Encorafenib can be decreased when combined with Eliglustat. Elvitegravir The metabolism of Encorafenib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Encorafenib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Encorafenib. Enasidenib The metabolism of Enasidenib can be decreased when combined with Encorafenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Encorafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Encorafenib. Entacapone The metabolism of Encorafenib can be decreased when combined with Entacapone. Entrectinib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib. Enzalutamide The serum concentration of Encorafenib can be decreased when it is combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Encorafenib. Ergotamine The metabolism of Encorafenib can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Encorafenib. Erlotinib The metabolism of Erlotinib can be decreased when combined with Encorafenib. Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Encorafenib. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Encorafenib. Escitalopram The serum concentration of Encorafenib can be increased when it is combined with Escitalopram. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Encorafenib. Etanercept The metabolism of Encorafenib can be increased when combined with Etanercept. Ethambutol The metabolism of Encorafenib can be decreased when combined with Ethambutol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Encorafenib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Etidocaine. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Encorafenib. Fedratinib The metabolism of Encorafenib can be decreased when combined with Fedratinib. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Encorafenib. Felodipine The metabolism of Encorafenib can be decreased when combined with Felodipine. Fenfluramine The metabolism of Encorafenib can be decreased when combined with Fenfluramine. Fesoterodine The metabolism of Encorafenib can be decreased when combined with Fesoterodine. Fexinidazole The risk or severity of adverse effects can be increased when Encorafenib is combined with Fexinidazole. Flecainide The metabolism of Flecainide can be decreased when combined with Encorafenib. Fluconazole The metabolism of Encorafenib can be decreased when combined with Fluconazole. Flunarizine The metabolism of Encorafenib can be decreased when combined with Flunarizine. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Encorafenib. Fluoxetine The serum concentration of Encorafenib can be increased when it is combined with Fluoxetine. Flupentixol The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Flupentixol. Fluphenazine The metabolism of Encorafenib can be decreased when combined with Fluphenazine. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Encorafenib. Fluvastatin The metabolism of Encorafenib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Encorafenib can be decreased when combined with Fluvoxamine. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Encorafenib. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Encorafenib. Fosnetupitant The metabolism of Encorafenib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Encorafenib can be increased when combined with Fosphenytoin. Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Encorafenib. Fusidic acid The metabolism of Encorafenib can be decreased when combined with Fusidic acid. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Encorafenib. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Encorafenib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Encorafenib. Gefitinib The metabolism of Encorafenib can be decreased when combined with Gefitinib. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Encorafenib. Gilteritinib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Gilteritinib. Givosiran The serum concentration of Encorafenib can be increased when it is combined with Givosiran. Glasdegib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib. Glycerol phenylbutyrate The metabolism of Encorafenib can be decreased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Encorafenib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Encorafenib. Grepafloxacin The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Grepafloxacin. Halofantrine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Encorafenib. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Encorafenib. Hydroxychloroquine The metabolism of Encorafenib can be decreased when combined with Hydroxychloroquine. Hydroxyzine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Encorafenib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encorafenib. Ibrutinib The metabolism of Encorafenib can be decreased when combined with Ibrutinib. Ibutilide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ibutilide. Idarubicin The metabolism of Encorafenib can be decreased when combined with Idarubicin. Iloperidone The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Iloperidone. Imatinib The serum concentration of Encorafenib can be increased when it is combined with Imatinib. Imipramine The metabolism of Encorafenib can be decreased when combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Encorafenib. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Encorafenib. Indinavir The metabolism of Encorafenib can be decreased when combined with Indinavir. Infliximab The metabolism of Encorafenib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Encorafenib. Ipecac The metabolism of Ipecac can be decreased when combined with Encorafenib. Isavuconazole The metabolism of Encorafenib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Encorafenib can be decreased when combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Encorafenib. Isoniazid The metabolism of Encorafenib can be decreased when combined with Isoniazid. Isradipine The metabolism of Encorafenib can be decreased when combined with Isradipine. Istradefylline The metabolism of Istradefylline can be decreased when combined with Encorafenib. Itraconazole The metabolism of Encorafenib can be decreased when combined with Itraconazole. Ivabradine Ivabradine may increase the QTc-prolonging activities of Encorafenib. Ivosidenib The metabolism of Encorafenib can be increased when combined with Ivosidenib. Ketoconazole The metabolism of Encorafenib can be decreased when combined with Ketoconazole. Labetalol The metabolism of Encorafenib can be decreased when combined with Labetalol. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Encorafenib. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Encorafenib. Lansoprazole The metabolism of Encorafenib can be decreased when combined with Lansoprazole. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Encorafenib. Lefamulin Lefamulin may increase the QTc-prolonging activities of Encorafenib. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Encorafenib. Letermovir The metabolism of Letermovir can be decreased when combined with Encorafenib. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Encorafenib. Levobetaxolol The metabolism of Encorafenib can be decreased when combined with Levobetaxolol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Encorafenib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Encorafenib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Encorafenib. Levoketoconazole The metabolism of Encorafenib can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Encorafenib. Levomilnacipran The metabolism of Encorafenib can be decreased when combined with Levomilnacipran. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Encorafenib. Lidocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Encorafenib. Linagliptin The metabolism of Encorafenib can be decreased when combined with Linagliptin. Lisdexamfetamine The metabolism of Encorafenib can be decreased when combined with Lisdexamfetamine. Lisuride The metabolism of Encorafenib can be decreased when combined with Lisuride. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Encorafenib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Encorafenib. Lonafarnib The metabolism of Encorafenib can be decreased when combined with Lonafarnib. Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Encorafenib. Lopinavir The serum concentration of Encorafenib can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Encorafenib can be decreased when combined with Lorcaserin. Lorpiprazole The metabolism of Encorafenib can be decreased when combined with Lorpiprazole. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Encorafenib. Lovastatin The metabolism of Encorafenib can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Encorafenib can be increased when combined with Lumacaftor. Lumefantrine The metabolism of Encorafenib can be decreased when combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Encorafenib. Macimorelin The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Macimorelin. Manidipine The metabolism of Encorafenib can be decreased when combined with Manidipine. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Encorafenib. Mavacamten The serum concentration of Encorafenib can be decreased when it is combined with Mavacamten. Meclizine The metabolism of Encorafenib can be decreased when combined with Meclizine. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Encorafenib. Meloxicam The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Meloxicam. Mephenytoin The metabolism of Encorafenib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Mepivacaine. Mepyramine The metabolism of Encorafenib can be decreased when combined with Mepyramine. Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Encorafenib. Metamfetamine The metabolism of Encorafenib can be decreased when combined with Metamfetamine. Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Encorafenib. Methimazole The metabolism of Encorafenib can be decreased when combined with Methimazole. Methotrimeprazine The metabolism of Encorafenib can be decreased when combined with Methotrimeprazine. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Encorafenib. Methoxyflurane The metabolism of Encorafenib can be decreased when combined with Methoxyflurane. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Encorafenib. Methylene blue The metabolism of Encorafenib can be decreased when combined with Methylene blue. Metoclopramide The metabolism of Encorafenib can be decreased when combined with Metoclopramide. Metoprolol The metabolism of Encorafenib can be decreased when combined with Metoprolol. Metreleptin The metabolism of Encorafenib can be increased when combined with Metreleptin. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Encorafenib. Mexiletine The metabolism of Encorafenib can be decreased when combined with Mexiletine. Mianserin The metabolism of Encorafenib can be decreased when combined with Mianserin. Miconazole The metabolism of Encorafenib can be decreased when combined with Miconazole. Midostaurin The metabolism of Encorafenib can be decreased when combined with Midostaurin. Mifepristone The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mifepristone. Milnacipran The metabolism of Encorafenib can be decreased when combined with Milnacipran. Minaprine The metabolism of Encorafenib can be decreased when combined with Minaprine. Mirabegron The serum concentration of Encorafenib can be increased when it is combined with Mirabegron. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Encorafenib. Mitotane The metabolism of Encorafenib can be increased when combined with Mitotane. Mizolastine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mobocertinib. Moclobemide The metabolism of Encorafenib can be decreased when combined with Moclobemide. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Encorafenib. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Encorafenib. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Encorafenib. Nadolol The metabolism of Encorafenib can be decreased when combined with Nadolol. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Encorafenib. Naloxone The metabolism of Encorafenib can be decreased when combined with Naloxone. Nateglinide The metabolism of Encorafenib can be decreased when combined with Nateglinide. Nebivolol The metabolism of Encorafenib can be decreased when combined with Nebivolol. Nefazodone The metabolism of Encorafenib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Encorafenib can be decreased when combined with Nelfinavir. Netupitant The metabolism of Encorafenib can be decreased when combined with Netupitant. Nevirapine The metabolism of Encorafenib can be decreased when combined with Nevirapine. Niacin The metabolism of Encorafenib can be decreased when combined with Niacin. Nicardipine The metabolism of Encorafenib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Encorafenib can be decreased when combined with Nicergoline. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Encorafenib. Nilotinib The metabolism of Encorafenib can be decreased when combined with Nilotinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Encorafenib. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Encorafenib. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Encorafenib. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Encorafenib. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Encorafenib. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encorafenib. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Encorafenib. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Encorafenib. Oliceridine The metabolism of Oliceridine can be decreased when combined with Encorafenib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Encorafenib. Omeprazole The metabolism of Encorafenib can be decreased when combined with Omeprazole. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Encorafenib. Opium The metabolism of Encorafenib can be decreased when combined with Opium. Oritavancin The metabolism of Encorafenib can be decreased when combined with Oritavancin. Orphenadrine The metabolism of Encorafenib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Encorafenib can be decreased when combined with Osilodrostat. Ospemifene The metabolism of Encorafenib can be decreased when combined with Ospemifene. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib. Oxamniquine The metabolism of Encorafenib can be decreased when combined with Oxamniquine. Oxatomide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Oxatomide. Oxetacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Oxetacaine. Oxprenolol The metabolism of Encorafenib can be decreased when combined with Oxprenolol. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Oxybuprocaine. Oxybutynin The metabolism of Encorafenib can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Encorafenib can be decreased when combined with Oxycodone. Oxymorphone The metabolism of Encorafenib can be decreased when combined with Oxymorphone. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib. Pacritinib The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Encorafenib. Paliperidone The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Paliperidone. Palonosetron The metabolism of Encorafenib can be decreased when combined with Palonosetron. Panobinostat The metabolism of Encorafenib can be decreased when combined with Panobinostat. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Encorafenib. Paroxetine The metabolism of Encorafenib can be decreased when combined with Paroxetine. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Encorafenib. Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Encorafenib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Encorafenib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Encorafenib. Peginterferon alfa-2b The metabolism of Encorafenib can be decreased when combined with Peginterferon alfa-2b. Penbutolol The metabolism of Encorafenib can be decreased when combined with Penbutolol. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Encorafenib. Pentobarbital The metabolism of Encorafenib can be increased when combined with Pentobarbital. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Encorafenib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Encorafenib. Phenobarbital The metabolism of Encorafenib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Phenol. Phenylbutyric acid The metabolism of Encorafenib can be decreased when combined with Phenylbutyric acid. Phenytoin The metabolism of Encorafenib can be increased when combined with Phenytoin. Pimozide The metabolism of Pimozide can be decreased when combined with Encorafenib. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Encorafenib. Pindolol The metabolism of Encorafenib can be decreased when combined with Pindolol. Piperazine The metabolism of Encorafenib can be decreased when combined with Piperazine. Pipotiazine The metabolism of Encorafenib can be decreased when combined with Pipotiazine. Pirfenidone The metabolism of Encorafenib can be decreased when combined with Pirfenidone. Pitolisant The serum concentration of Encorafenib can be decreased when it is combined with Pitolisant. Ponatinib The metabolism of Ponatinib can be decreased when combined with Encorafenib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Encorafenib. Posaconazole The metabolism of Encorafenib can be decreased when combined with Posaconazole. Practolol The metabolism of Encorafenib can be decreased when combined with Practolol. Pramocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Pramocaine. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Encorafenib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Encorafenib. Prilocaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Prilocaine. Primaquine The metabolism of Encorafenib can be decreased when combined with Primaquine. Primidone The metabolism of Encorafenib can be increased when combined with Primidone. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Encorafenib. Procainamide The metabolism of Procainamide can be decreased when combined with Encorafenib. Procaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Encorafenib. Progesterone The metabolism of Encorafenib can be decreased when combined with Progesterone. Proguanil The metabolism of Encorafenib can be decreased when combined with Proguanil. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Encorafenib. Promethazine The metabolism of Encorafenib can be decreased when combined with Promethazine. Propafenone The metabolism of Encorafenib can be decreased when combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Encorafenib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Propoxycaine. Propranolol The metabolism of Encorafenib can be decreased when combined with Propranolol. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Encorafenib. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Encorafenib. Quinidine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Quinidine. Quinine The metabolism of Encorafenib can be decreased when combined with Quinine. Ranitidine The metabolism of Encorafenib can be decreased when combined with Ranitidine. Ranolazine The serum concentration of Encorafenib can be increased when it is combined with Ranolazine. Reboxetine The metabolism of Encorafenib can be decreased when combined with Reboxetine. Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Encorafenib. Remoxipride The metabolism of Encorafenib can be decreased when combined with Remoxipride. Revefenacin The metabolism of Revefenacin can be decreased when combined with Encorafenib. Ribociclib The metabolism of Encorafenib can be decreased when combined with Ribociclib. Rifampicin The metabolism of Encorafenib can be increased when combined with Rifampicin. Rifamycin The metabolism of Encorafenib can be increased when combined with Rifamycin. Rifapentine The metabolism of Encorafenib can be increased when combined with Rifapentine. Rilonacept The metabolism of Encorafenib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Encorafenib can be decreased when combined with Rilpivirine. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Encorafenib. Ritonavir The serum concentration of Encorafenib can be increased when it is combined with Ritonavir. Rolapitant The metabolism of Encorafenib can be decreased when combined with Rolapitant. Romidepsin The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin. Ropeginterferon The metabolism of Encorafenib can be decreased when combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Encorafenib. Rotigotine The metabolism of Encorafenib can be decreased when combined with Rotigotine. Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Encorafenib. Rucaparib The metabolism of Encorafenib can be decreased when combined with Rucaparib. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Encorafenib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Encorafenib. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Encorafenib. Saquinavir The metabolism of Encorafenib can be decreased when combined with Saquinavir. Satralizumab The serum concentration of Encorafenib can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Encorafenib can be increased when combined with Secukinumab. Selegiline The metabolism of Encorafenib can be decreased when combined with Selegiline. Sertindole The metabolism of Encorafenib can be decreased when combined with Sertindole. Sertraline The metabolism of Encorafenib can be decreased when combined with Sertraline. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Encorafenib. Sildenafil The metabolism of Encorafenib can be decreased when combined with Sildenafil. Siltuximab The metabolism of Encorafenib can be increased when combined with Siltuximab. Simeprevir The metabolism of Encorafenib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Encorafenib can be decreased when combined with Simvastatin. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Encorafenib. Somatrogon The metabolism of Encorafenib can be increased when combined with Somatrogon. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Encorafenib. Sotalol The metabolism of Sotalol can be decreased when combined with Encorafenib. Sotorasib The serum concentration of Encorafenib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Sparfloxacin. St. John's Wort The metabolism of Encorafenib can be increased when combined with St. John's Wort. Stiripentol The metabolism of Encorafenib can be decreased when combined with Stiripentol. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Encorafenib. Sulfaphenazole The metabolism of Encorafenib can be decreased when combined with Sulfaphenazole. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Encorafenib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Encorafenib. Sultopride The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Sultopride. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Encorafenib. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encorafenib. Tafenoquine The metabolism of Encorafenib can be decreased when combined with Tafenoquine. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Encorafenib. Tamsulosin The metabolism of Encorafenib can be decreased when combined with Tamsulosin. Tegaserod The metabolism of Encorafenib can be decreased when combined with Tegaserod. Telaprevir The metabolism of Encorafenib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Encorafenib. Telithromycin The metabolism of Encorafenib can be decreased when combined with Telithromycin. Pregnancy and Lactation TGA pregnancy category D: US FDA pregnancy category Not Assigned Pregnancy Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. Lactation The effects in the nursing infant are unknown. Women should be advised not to breastfeed during therapy with this drug and for 2 weeks after the final dose. How should this medicine be used?

Encorafenib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take encorafenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take encorafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. If you vomit after taking the medication,…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)